tiprankstipranks
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Holding CRVS?
Track your performance easily

Corvus Pharmaceuticals (CRVS) Income Statement

536 Followers

Corvus Pharmaceuticals Income Statement

Last quarter (Q3 2024), Corvus Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Corvus Pharmaceuticals's net income was $-40.22M. See Corvus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 25.09M$ 23.41M$ 32.56M$ 38.63M$ 43.76M$ 48.85M
Operating Income
$ -25.09M$ -23.41M$ -32.56M$ -38.63M$ -43.76M$ -48.85M
Net Non Operating Interest Income Expense
$ -1.58M$ -1.58M$ -654.00K---
Other Income Expense
$ 43.10M$ -5.21M$ -9.40M$ 4.83M$ -37.23M-
Pretax Income
$ -54.75M$ -27.03M$ -41.31M$ -43.46M$ -6.54M$ -48.85M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
$ -1.26M-----
Net Income Common Stockholders
$ -56.83M$ -27.03M$ -41.31M$ -43.24M$ -6.00M$ -46.67M
Basic EPS
$ -0.92$ -0.56$ -0.89$ -1.03$ -0.20$ -1.59
Diluted EPS
$ -0.92$ -0.56$ -0.89$ -1.03$ -0.20$ -1.59
Basic Average Shares
$ 224.53M$ 48.03M$ 46.55M$ 41.85M$ 29.48M$ 29.35M
Diluted Average Shares
$ 224.53M$ 48.03M$ 46.55M$ 41.85M-$ 29.35M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 25.09M$ 23.41M$ 32.56M$ 38.63M$ 43.76M$ 48.85M
Net Income From Continuing And Discontinued Operation
$ -56.83M$ -27.03M$ -41.31M$ -43.24M$ -6.00M$ -46.67M
Normalized Income
$ -5.14M$ -22.67M----
Interest Expense
------
EBIT
$ -56.38M$ -23.41M$ -32.56M$ -38.63M$ -43.76M$ -48.85M
EBITDA
$ -56.14M$ -23.26M$ -32.20M$ -38.17M$ -43.13M$ -48.11M
Currency in USD

Corvus Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis